首页> 外文OA文献 >Clinical and pre-clinical pharmacokinetics of green tea polyphenols
【2h】

Clinical and pre-clinical pharmacokinetics of green tea polyphenols

机译:绿茶多酚的临床和临床前药代动力学

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Tea consumption has been suggested to have beneficial effects for human health, especially in cancer prevention. At present, epidemiological evidence of the protective effect of tea consumption against the development of human cancer is not conclusive. Interpretation of epidemiological data and extrapolation of rodent data to humans are generally hampered by inadequate information on the bioavailability and pharmacokinetics of tea constituents. We have performed studies to determine the pharmacokinetics of green tea in humans after single and multiple oral dose administration of tea polyphenols and the contribution of hepatic first-pass elimination to the low oral bioavailability of green tea catechins in animals. EGCG was present in the systemic blood in the unchanged form in humans after oral administration of two green tea polyphenol products, EGCG and Polyphenon E (a mixture of major green tea polyphenols). Oral administration of EGCG and Polyphenon E resulted in similar systemic exposure of EGCG. EGC and EC were present in glucuronic acid/sulfate conjugates in blood and urine samples after the Polyphenon E administration. Large inter-subject variations in the systemic levels of green tea catechins were observed following oral administration of green tea polyphenols. We found that it is safe for healthy human subjects to take green tea polyphenols for four weeks in amounts equivalent to those contained in 8 to 16 cups of green tea once a day or in divided doses twice a day. Systemic availability of EGCG increased more than 60% after chronic green tea polyphenol administration at high doses once a day. Oral administration of green tea polyphenols at the selected doses and dosing schedules did not elicit overall changes in the selected pharmacodynamic measurements. Oral bioavailability of green tea catechins was demonstrated to be low in animals and possibly in humans. Based on our pre-clinical study, we found that first-pass hepatic elimination of green tea catechins didn't play a significant role in the presystemic elimination of orally administered catechins. Factors within the gastrointestinal tract such as limited membrane permeability, transporter mediated intestinal secretion, or gut wall metabolism may contribute more significantly to the low oral bioavailability of green tea catechins.
机译:已建议食用茶对人体健康,特别是在预防癌症方面具有有益的作用。目前,尚无关于饮用茶对人类癌症发展具有保护作用的流行病学证据。关于茶叶成分的生物利用度和药代动力学的信息不足,通常会​​阻碍流行病学数据的解释和啮齿动物数据对人类的外推。我们进行了研究,以确定单次或多次口服茶多酚后绿茶在人体内的药代动力学,以及肝首过消除对动物中绿茶儿茶素的低口服生物利用度的影响。口服两种绿茶多酚产品EGCG和Polyphenon E(主要绿茶多酚的混合物)后,EGCG以不变的形式存在于人体的全身血液中。口服EGCG和Polyphenon E导致类似的EGCG全身暴露。施用Polyphenon E后,血液和尿液样品中的葡萄糖醛酸/硫酸盐结合物中存在EGC和EC。口服绿茶多酚后,观察到受试者体内绿茶儿茶素的体内水平存在较大差异。我们发现,健康的人类受试者可以安全地服用绿茶多酚4周,其剂量相当于每天一次8到16杯绿茶中的含量或每天两次分次服用。在每天一次以高剂量长期服用绿茶多酚后,EGCG的全身利用率增加了60%以上。以选定的剂量和给药时间表口服绿茶多酚未引起选定药效学测量的总体变化。绿茶儿茶素的口服生物利用度在动物和人类中均较低。根据我们的临床前研究,我们发现,肝脏通过的绿茶儿茶素的首过清除在口服给予儿茶素的系统性清除中没有发挥重要作用。胃肠道内的因素,例如有限的膜通透性,转运蛋白介导的肠道分泌或肠壁代谢,可能对绿茶儿茶素的低口服生物利用度有更大的影响。

著录项

  • 作者

    Cai Yan;

  • 作者单位
  • 年度 2002
  • 总页数
  • 原文格式 PDF
  • 正文语种 en_US
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号